Literature DB >> 1438177

Comparative molecular modeling and crystallization of P-30 protein: a novel antitumor protein of Rana pipiens oocytes and early embryos.

S C Mosimann1, K L Johns, W Ardelt, S M Mikulski, K Shogen, M N James.   

Abstract

The P-30 protein (Onconase) of Rana pipiens oocytes and early embryos is homologous to members of the pancreatic ribonuclease superfamily and exhibits an antitumor activity in vitro and in vivo. It appears that the ribonucleolytic activity of P-30 protein may be required for its antitumor effects. A comparative molecular model of P-30 protein has been constructed based upon the known three-dimensional structure of bovine pancreatic RNase A in order to provide structural information. Functionally, these enzymes hydrolyze oligoribonucleotides to pyrimidine-3'-phosphate monoesters and 5'-OH ribonucleotides. In the modeling procedure, automated sequence alignments were revised based upon the inspection of the RNase A structure before the amino acids of the P-30 protein were assigned the coordinates of the RNase A template. The inevitable intermolecular steric clashes that result were relieved on an interactive graphics device through the adjustment of side chain torsion angles. This process was followed by energy minimization of the model, which served to optimize stereochemical geometry and to relieve any remaining unacceptably close contacts. The resulting model retains the essential features of RNase A as sequence insertions and deletions are almost exclusively found in exposed surface loops. The all atom superposition of active site residues of the P-30 protein model and an identically minimized RNase A structure has a root mean square deviation of 0.52 A. Though tentative, the model is consistent with a pyrimidine specificity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438177     DOI: 10.1002/prot.340140308

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  6 in total

1.  RNase inhibition of human immunodeficiency virus infection of H9 cells.

Authors:  R J Youle; Y N Wu; S M Mikulski; K Shogen; R S Hamilton; D Newton; G D'Alessio; M Gravell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

2.  A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.

Authors:  N J Vogelzang; M Aklilu; W M Stadler; M C Dumas; S M Mikulski
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity.

Authors:  B O Villoutreix; O Teleman; B Dahlbäck
Journal:  J Comput Aided Mol Des       Date:  1997-05       Impact factor: 3.686

Review 4.  Leczyme: a new candidate drug for cancer therapy.

Authors:  Takeo Tatsuta; Shigeki Sugawara; Kohta Takahashi; Yukiko Ogawa; Masahiro Hosono; Kazuo Nitta
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

Review 5.  Cancer-selective induction of apoptosis by leczyme.

Authors:  Takeo Tatsuta; Shigeki Sugawara; Kohta Takahashi; Yukiko Ogawa; Masahiro Hosono; Kazuo Nitta
Journal:  Front Oncol       Date:  2014-06-04       Impact factor: 6.244

6.  Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.

Authors:  Camillo Porta; Chiara Paglino; Luciano Mutti
Journal:  Biologics       Date:  2008-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.